JP2023549537A5 - - Google Patents
Info
- Publication number
- JP2023549537A5 JP2023549537A5 JP2023528957A JP2023528957A JP2023549537A5 JP 2023549537 A5 JP2023549537 A5 JP 2023549537A5 JP 2023528957 A JP2023528957 A JP 2023528957A JP 2023528957 A JP2023528957 A JP 2023528957A JP 2023549537 A5 JP2023549537 A5 JP 2023549537A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- antibody
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063114479P | 2020-11-16 | 2020-11-16 | |
| US63/114,479 | 2020-11-16 | ||
| US202163237526P | 2021-08-26 | 2021-08-26 | |
| US63/237,526 | 2021-08-26 | ||
| PCT/US2021/059444 WO2022104236A2 (en) | 2020-11-16 | 2021-11-16 | Multispecific antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549537A JP2023549537A (ja) | 2023-11-27 |
| JP2023549537A5 true JP2023549537A5 (https=) | 2024-11-20 |
Family
ID=81601772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528957A Pending JP2023549537A (ja) | 2020-11-16 | 2021-11-16 | 多重特異性抗体およびその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230399408A1 (https=) |
| EP (1) | EP4243938A4 (https=) |
| JP (1) | JP2023549537A (https=) |
| WO (1) | WO2022104236A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022525275A (ja) | 2019-03-28 | 2022-05-12 | エービー ストゥーディオ インコーポレイテッド | ヘテロ多量体タンパク質及びその使用法 |
| EP4243938A4 (en) * | 2020-11-16 | 2025-03-05 | AB Therapeutics, Inc. | Multispecific antibodies and uses thereof |
| CN119948063A (zh) * | 2022-06-23 | 2025-05-06 | 信达生物制药(苏州)有限公司 | 结合egfr和b7-h3的双特异性抗体 |
| CA3260255A1 (en) * | 2022-06-29 | 2024-01-04 | Doma Biopharmaceutical (Suzhou) Co., Ltd. | EGFR/MET ANTIBODIES AND THEIR USES |
| KR20260005269A (ko) * | 2023-04-24 | 2026-01-09 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | c-Met를 표적으로 하는 다중 특이성 항체 |
| AU2024315062A1 (en) * | 2023-07-28 | 2026-03-12 | Tigatx, Inc. | Engineered iga antibodies and methods of use |
| WO2025025434A1 (zh) * | 2023-08-02 | 2025-02-06 | 百泰生物药业有限公司 | EGFR/c-Met双特异性抗体及其应用 |
| WO2025042806A2 (en) * | 2023-08-21 | 2025-02-27 | Modernatx, Inc. | C-met binding antibodies, nucleic acids encoding same, and methods of use |
| WO2026021476A1 (en) * | 2024-07-24 | 2026-01-29 | Beone Guangzhou Biologics Manufacturing Co., Ltd. | Anti-cmet and anti-egfr multispecific antibody drug conjugates |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| EP2621953B1 (en) * | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| EP2723771B1 (en) * | 2011-06-23 | 2019-09-11 | Ablynx NV | Serum albumin binding proteins |
| US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| SG11202001050PA (en) * | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
| KR20200118423A (ko) * | 2018-01-08 | 2020-10-15 | 난징 레전드 바이오테크 씨오., 엘티디. | 다중특이성 항원 결합 단백질 및 이의 사용 방법 |
| CN113508134B (zh) * | 2019-02-22 | 2024-12-03 | 安维达生物科技公司 | 白蛋白结合抗体及其用途 |
| JP2022525275A (ja) * | 2019-03-28 | 2022-05-12 | エービー ストゥーディオ インコーポレイテッド | ヘテロ多量体タンパク質及びその使用法 |
| US11879013B2 (en) * | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| EP4243938A4 (en) * | 2020-11-16 | 2025-03-05 | AB Therapeutics, Inc. | Multispecific antibodies and uses thereof |
-
2021
- 2021-11-16 EP EP21893000.6A patent/EP4243938A4/en active Pending
- 2021-11-16 US US18/036,200 patent/US20230399408A1/en active Pending
- 2021-11-16 WO PCT/US2021/059444 patent/WO2022104236A2/en not_active Ceased
- 2021-11-16 JP JP2023528957A patent/JP2023549537A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023549537A5 (https=) | ||
| JP7840836B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP2022101693A5 (https=) | ||
| JP2021528973A5 (https=) | ||
| JP2017529838A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2023516004A5 (https=) | ||
| JP2022553922A5 (https=) | ||
| JP2024532489A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| JP7755062B2 (ja) | 新規抗ｌ１ｃａｍ抗体 | |
| JP2022545741A5 (https=) | ||
| JP2023548529A5 (https=) | ||
| JP2024537323A5 (https=) | ||
| JP2021525806A5 (https=) | ||
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2022532991A5 (https=) | ||
| JP2022512672A5 (https=) | ||
| JP2024515560A5 (https=) | ||
| JP2025508317A5 (https=) | ||
| JP2023517794A5 (https=) | ||
| JP2025503229A5 (https=) |